Science & Environment

Research

The Latest

UC San Diego Ranked 3rd Among U.S. Public Universities in High-Quality Research

The University of California San Diego ranked 3rd among public research universities in the United States in this year’s annual ranking of high-quality scientific research papers by the journal Nature. In the Nature Index 2018 Annual Tables, the La Jolla campus ranked 12th in the world out of 500 institutions and 6th among U.S. universities in the research results its faculty, students and staff others published in 82 high-quality journals in 2017.

What’s Inside Your Medical Record?

Patients at UC San Diego Health can now read the medical notes signed by their primary care physician. This move toward transparency is part of an international trend to make patients feel more in control of their health care.

Antibody Blocks Inflammation, Protects Mice from Hardened Arteries and Liver Disease

Researchers at University of California San Diego School of Medicine discovered that they can block inflammation in mice with a naturally occurring antibody that binds oxidized phospholipids (OxPL), molecules on cell surfaces that get modified by inflammation. Even while on a high-fat diet, the antibody protected the mice from arterial plaque formation, hardening of the arteries and liver disease, and prolonged their lives.

UC San Diego Tops List of World’s ‘Golden Age’ Universities

For the second year in a row, the London-based Times Higher Education ranked UC San Diego the world’s number one research university founded during the “golden age” of higher education development, in the two decades between 1945 and 1967—when higher education was characterized by rapid university expansion and increasing investment in research.

Phase I Trial Finds Experimental Drug Safe in Treating Chronic Lymphocytic Leukemia

Reporting results from a first-in-human phase I clinical trial, researchers at University of California San Diego School of Medicine have found that treatment with cirmtuzumab, an experimental monoclonal antibody-based drug, measurably inhibited the “stemness” of chronic lymphocytic leukemia cancer (CLL) cells — their ability to self-renew and resist terminal differentiation and senescence.

Stem Cell-Based Phase I Trial to Repair Spinal Cord Injuries Produces Encouraging Results

Researchers at University of California San Diego School of Medicine report that a first-in-human phase I clinical trial in which neural stem cells were transplanted into participants with chronic spinal cord injuries produced measurable improvement in three of four subjects, with no serious adverse effects.